Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +160.00% and +14.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?